Scopolamine is an anticholinergic drug that acts as a competitive antagonist of muscarinic acetylcholine receptors, primarily targeting the M1 and M3 subtypes. In cluster headache treatment, it potentially modulates parasympathetic neural activity and neurotransmitter signaling, which may help reduce the frequency and intensity of autonomic symptoms associated with these severe headaches. Its central nervous system effects can provide symptomatic relief by disrupting cholinergic pathways involved in pain perception and autonomic dysregulation.